TScan Therapeutics, Inc (TCRX) Announces Launch of Proposed Public Offering of Common Stock, Warrants

TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that it has commenced an underwritten public offering of shares of voting common stock and, in lieu of voting common stock to investors that so choose, non-voting common stock and pre-funded warrants to purchase shares of common stock. All shares of common stock and pre-funded warrants to be sold in the offering will be offered by TScan. TScan intends to grant the underwriters a 30-day option to purchase additional shares of its voting common stock in an amount equal to 15% of the securities offered in the public offering. The offering is subject to market, regulatory and other conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Morgan Stanley and Wedbush PacGrow are acting as joint book-running managers for the offering.

The Company intends to use the net proceeds from the offering for general corporate purposes.

You May Also Be Interested In

• DoorDash (DASH) Appoints Jeffrey Blackburn to its Board
• Kartoon Studios (TOON) Prices 7M Share Offering at $1/sh
• Bio-Path Holdings (BPTH) Announces 375K Share Offering at $3.225/sh